PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients with LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)

Last updated: November 5, 2024
Sponsor: National Cancer Institute, Naples
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Stereotactic Body Radiation Therapy (SBRT)

Clinical Study ID

NCT04854213
88/20
  • Ages 18-80
  • All Genders

Study Summary

PRELUDE-1 study is a pilot intervention trial that aims to describe the immunologic and genetic evolutions induced by stereotactic body radiationtherapy (SBRT) treatment in oligometastatic Colorectal Cancer (omCRC) patients with two-three nodules lung-limited disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age <80 years

  • Cytological or histological diagnosis of colorectal adenocarcinoma

  • Two or three asymptomatic lung nodules smaller than 25 mm

  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1

  • Available Formalin Fixed Paraffin Embedded (FFPE) of resected primary tumor

  • Negative pregnancy test for all potentially childbearing women

  • Patient candidates to SBRT

Exclusion

Exclusion Criteria:

  • Previous systemic anti-tumor treatments (allowed treatment with capecitabine orfluorouracil and radiotherapy in the neoadjuvant setting of rectal tumors withtherapy terminated at least 6 months before)

  • Neutrophils <2000/mm³ or platelets <100.000/mm³ or hemoglobin <9 g/dl; serumcreatinine level> 1.5 times the maximum normal value; GOT and/or GPT >5 times themaximum normal value and/or bilirubin level >3 times the maximum normal value

  • Previous or concomitant malignant neoplasms (excluding basal or spinocellularcutaneous carcinoma or in situ carcinoma of the uterine cervix)

  • Active or uncontrolled infections

  • Other concomitant uncontrolled diseases or conditions contraindicating the studydrugs at clinician evaluation

  • Presence of brain metastases

  • Refusal or inability to provide informed consent

  • Impossibility to guarantee follow-up

Study Design

Total Participants: 25
Treatment Group(s): 1
Primary Treatment: Stereotactic Body Radiation Therapy (SBRT)
Phase:
Study Start date:
October 06, 2021
Estimated Completion Date:
March 31, 2025

Study Description

PRELUDE-1 study is a monocentric pilot interventional trial. The study concerns all patients enrolled with a diagnosis of oligometastatic Colorectal Cancer (omCRC) with two-three nodules lung-limited disease and treated with SBRT technique. SBRT will be delivered according to a risk-adapted protocol.

Tumor genetic background will be assessed on primary FFPE (Formalin Fixed Paraffin Embedded) tissues. Liquid biopsy will be done on blood samples collected before radiotherapy (RT) start and after 40 days to monitor tumor DNA evolution. The most direct method to assess cancer genetics relies on sampling of tumor DNA and its characterization through whole genome sequencing techniques (NGS, Next Generation Sequencing).

The study will last 48 months, divides as follow: 24 months of enrollment phase and up to 24 months of follow-up. Follow-up will be performed on the 40th day after the end of radiation treatment and then every 3 months until progression.

Connect with a study center

  • Istituto Nazionale Tumori - Fondazione G. Pascale

    Napoli, 80131
    Italy

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.